Press Releases

11/08/2023

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease mode...

11/07/2023

Tempus Welcomes Rush University Medical Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that Rush University Medical Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research...

11/03/2023

Tempus Announces New ctDNA Assay, xM Monitor

Tumor uninformed treatment response monitoring assay for research use only Tempus, a leader in artificial intelligence and precision medicine, today announced xM Monitor (formerly xF Monitor) – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy fo...

11/01/2023

Tempus Announces Eight Abstracts Accepted For Presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023. "We continue to be a leader in the advancement of immunotherapy research, as evidenced...

10/20/2023

Oncology

Tempus Announces Five Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023. "We are excited to share our latest research at ESMO this year, as we continue to make our precision medici...

08/22/2023

Tempus Welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers t...

08/15/2023

Oncology

FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced b...

07/12/2023

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

Study aims to create the most robust, multi-omic dataset for patients with NSCLC Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset...

07/06/2023

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

Diagnostic will be used to prospectively assess HLA loss in patients’ tumors and guide appropriate treatment selection in TScan’s solid tumor clinical trial Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical...

06/21/2023

Tempus Launches Standalone RNA Sequencing Test, xR

Tempus, a leader in artificial intelligence and precision medicine, today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. Tempus has always understood the importa...

NEWS

Media Coverage

Additional Partnerships